Wednesday - May 7, 2025

LOGIN  |  REGISTER
C4 Therapeutics
Assertio

I-Mab to Participate at the Jefferies Global Healthcare Conference

May 22, 2024 | Last Trade: US$0.89 0.04 4.33

ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.

Jefferies Global Healthcare Conference

Presentation Time

Wednesday, June 5 at 9:30 a.m. EST

Presenters

Raj Kannan, CEO; Louie Naumovski, Interim CMO

Webcast link

Here

Meetings

One-on-one and small group meetings: June 5, 2024

Management
Participants

Raj Kannan, CEO

Joe Skelton, CFO

Louie Naumovski, Interim CMO

Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab's IR website at https://ir.i-mabbiopharma.com/

For more information, please contact your Jefferies representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit  https://ir.i-mabbiopharma.com/ and follow us on LinkedIn and X.

For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com 

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page